Regeneron Surges on 1.09% Rally Amid 182nd Liquidity Rank as Analysts Flag Undervalued Catalysts

, 2025, , ranking 182nd among stocks in terms of liquidity. The stock remains a focal point for investors assessing its asymmetric upside potential amid a maturing pipeline and durable revenue streams.

Analysts highlight Regeneron’s undervaluation relative to biotech peers, . This discount reflects underpricing of near-term catalysts, including the expansion of Dupixent into chronic obstructive pulmonary disease () and pediatric indications. , , supported by intellectual property protection through 2034.

Key late-stage developments include itepekimab, a COPD candidate, . While AERIFY-2 results were mixed, regulatory discussions for a 2026 Biologics License Application are underway. Additionally, cemdisiran, an for generalized myasthenia gravis, demonstrated statistically significant improvements in patient function and is expected to file for U.S. approval in early 2026.

The September 8, 2025, presentation at the Morgan Stanley Healthcare Conference could act as a re-rating catalyst. , driven by regulatory milestones and strategic clarity. The event may also clarify paths forward for itepekimab and cemdisiran, addressing mixed trial data and market access strategies.

To run this back-test accurately, confirm the stock universe (e.g., Russell 3000 common stocks), re-balancing conventions (buy/sell timing, transaction costs), and data source preferences (OHLC prices, exchange volume). Let me know if default parameters suffice for immediate execution.